Texas Yale Capital Corp. Logic Bio Therapeutics, Inc. Call Options Transaction History

Texas Yale Capital Corp.

  • $2.09 Billion
  • Q2 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About LogicBio Therapeutics, Inc.

LOGC Quotes by TradingView
  • Ticker LOGC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,962,700
  • Description
  • LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...
More about LOGC
Track This Portfolio

Track Texas Yale Capital Corp. Portfolio

Follow Texas Yale Capital Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Texas Yale Capital Corp., based on Form 13F filings with the SEC.

News

Stay updated on Texas Yale Capital Corp. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email